DBDana Bailey

Dana Bailey

*This is an algorithmically generated author record based on publicly available information.

Dana Bailey has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    False Calm and False Alarm: A Qualitative Study of Confusion and Misinterpretation of a Laboratory Results Graph

    by Helen Monkman, Amelia Schmit, Dana Nyholt, Leah MacDonald, Blake Lesselroth

    Health consumers (i.e., citizens), increasingly review their personal health information on patient portals. However, health information, especially graphs, can be difficult to interpret and use. To investigate reporting attributes that confused participants, what they misinterpreted, and their follow-up intentions, we examined participants’ (N = 24) think-aloud responses to a laboratory system graph depicting lab values over time. Overall, 18 participants expressed confusion at least once and 12 misinterpreted one or more aspects of the graph. Common areas of confusion included axis labelling and the significance of value changes. Confusion led to misinterpretation (e.g., incorrect date, more than two results depicted, change was not important). The findings underscore the need for improved graph design. To enhance user performance with laboratory graphs, we recommend implementing generic design principles for graphs and exploring potential strategies unique to this context (e.g., standardized Y axes values, personalized reference ranges, inclusion of explanatory text). This research emphasizes the importance and value of user-centered design for improving health information for citizens.


  • Open Access

    Is There Value Without Context? A Survey Evaluating How Laboratory Test Results Are Presented to Patients in Canada

    by Dana Nyholt, Helen Monkman

    Although direct reporting of laboratory test results to patients improves engagement and utilization of healthcare services, this assumes that results are presented in a manner that can be comprehended and acted upon by patients. To evaluate the practice of patient reporting across Canadian laboratories, a voluntary survey was distributed. 22 responses were received from laboratories and laboratory networks nationwide, representative of the range of Canadian laboratory and patient demographics. Despite the Connected Care for Canadians Act being passed in June 2024, one-third of respondents do not provide results to patients. Of those that do, results largely replicate physician reports and are heterogeneous between labs, with different strategies used to present data and flag abnormalities. A minority of labs suppress some testing from patient receipt, modify reports to improve patient comprehension, or provide graphs to support interpretation and trending. Laboratory professionals largely agreed that there are benefits in modifying reports to aid in patient comprehension but expressed concern that patient health literacy is currently in adequate. This may lead to increased anxiety, misinterpretation of results, follow-up questions, self-diagnosis, and undue stress until a healthcare provider could be consulted. Collaboration with patients and healthcare providers is necessary to develop guidelines on meaningful direct-to-patient reporting.


  • Open Access

    What People Know vs. What They Should Know About Laboratory Reference Ranges

    by Dana Bailey, Leah MacDonald, Helen Monkman

    Laboratory test results are increasingly available to health consumers. Almost all test results are accompanied by a reference range to aid in interpretation. This study asked 25 non-healthcare providers to explain the term reference range. The descriptions highlighted four principal themes: health consumers were unsure about their understanding of the term reference range; they equated a reference range with a normal range; few had some degree of awareness of the limitations of reference ranges; and few had limited awareness of the difference between a reference range and clinical cutoff. Further efforts should be made to educate health consumers on the utility and limitations of reference ranges. When providing results to health consumers, laboratories should consider including other means of contextualizing test results in order to support their understanding of potential clinical significance.

  • Open Access

    A Comparison of Websites Offering Laboratory Test Information Targeted to Citizens

    by Helen Monkman, Dana Bailey

    Laboratory (lab) tests can assist diagnosis, treatment, and monitoring illness and health. Lab results are one of the most commonly accessible types of personal health information, yet they can be difficult for consumers (e.g., patients, laypeople, citizens) to understand. Consequently, many consumers turn to digital educational resources (e.g., websites, mobile applications) to make sense of their tests and results. In this study, we compared the understandability and readability of four different consumer targeted webpages with information about a commonly ordered blood test called the Complete Blood Count (CBC). The webpages varied in terms of understandability, and only one met the threshold. None of the web pages provided any information about how to respond to lab results. Although all four webpages were quite readable, some were much longer than others. The length of webpages may impact users’ attention, ability to locate information, and determine what is most important. Future work is warranted to better understand users’ information needs and the usability and user experience of these types of websites.

  • Open Access

    Use of MALDI-TOF for Diagnosis of Microbial Infections

    by Dana Bailey, Eleftherios P. Diamandis, Gilbert Greub, Susan M. Poutanen, Jens Jørgen Christensen, Markus Kostrzew

    Although mass spectrometry is making its mark on all facets of clinical laboratory medicine, arguably no field is witnessing its impact more than clinical microbiology. The application of MALDI-TOF mass spectrometry (MALDI-TOF MS) to microbial identification is revolutionizing clinical microbiology by providing rapid identification with minimal sample preparation at a potential savings in costs. Across the globe, the degree of implementation of MALDI-TOF MS varies markedly. In Canada, Australia, and much of Europe, MALDI platforms are in routine use in clinical microbiology, whereas the US Food and Drug Administration has yet to provide clinical clearance. In this Q&A, 4 experts from across the globe with first-hand experience implementing MALDI-TOF MS in the microbiology laboratory provide insight into what this technology can and cannot provide, what it takes to bring it in house, and what direction it takes us in the future. The application of MALDI-TOF MS to the diagnosis of microbial infections has been touted as a revolution in clinical microbiology. However, no technology is without its pitfalls. Can you please describe what you feel are the greatest strengths and limitations of MALDI-TOF MS? Gilbert Greub: When it is used to identify bacterial strains and fungi, the main strengths of MALDI-TOF MS are the rapidity of the technique (<10 min), its low cost in terms of reagents and technician processing time [<2 Euros (95% accuracy at the species level. One of the most important limitations of this technique is its relatively low analytical sensitivity (about 105–106 bacteria/well). Thus, the accuracy of the identification is increased when the identification is done on a colony grown on agar or on a blood culture pellet, i.e., after a culture-based amplification step. Consequently, MALDI-TOF MS is not a tool currently suitable to detect …


  • Acquired severe hypercholesterolemia and hypoalphalipoproteinemia

    by Zuhier Awan, Dana Bailey, Anouar Hafiane, Jacques Genest